



Review article

Coffee and metabolic impairment: An updated review of epidemiological studies

Silvio Buscemi ^a, Stefano Marventano ^{b,*}, Mariagrazia Antoci ^b, Antonella Cagnetti ^b, Gabriele Castorina ^b, Fabio Galvano ^c, Marina Marranzano ^b, Antonio Mistretta ^b

^a Dipartimento Biomedico di Medicina Interna e Specialistica (DIBIMIS), University of Palermo, Palermo, Italy

^b Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, Catania, Italy

^c Department of Biomedical and Biotechnological Sciences, Section of Biochemistry, University of Catania, Catania, Italy

ARTICLE INFO

Article history:

Received 8 December 2015

Accepted 3 February 2016

Available online 13 February 2016

Keywords:

Coffee

Caffeine

Metabolic disorders

Diabetes

ABSTRACT

Background: Coffee is one of the most consumed beverages worldwide. In the last years, coffee consumption has been associated with a number of beneficial effects against metabolic impairment. The aim of this narrative review was to report the most updated and comprehensive evidence from epidemiological and experimental studies as well as mechanisms of action of coffee on metabolic impairment.

Methods: A search in electronic databases (PUBMED and EMBASE) was performed to retrieve systematic and pooled analyses on coffee and diabetes, hypertension, and dyslipidemia. Furthermore, the most accredited hypotheses and mechanisms of action of coffee have been described.

Results: Coffee consumption has been associated with reduced risk of diabetes in observational studies. However, the effect seems not to be mediated by caffeine. Contrasting results have been found in pooled analyses of observational studies on hypertension, despite short- and long-term follow-ups that have been demonstrated to influence the outcome. Poor or little effect on plasma lipids has been reported in studies on acute administration of coffee, yet depending on the type of coffee preparation. The main beneficial effects of coffee consumption seem to rely on the content of antioxidant and anti-inflammatory compounds (i.e., polyphenols). Among the most important, chlorogenic acids have demonstrated direct anti-hypertensive action through beneficial effect on endothelial function, and significant improvement in glucose and insulin metabolism. Also, diterpenes and melanoidins are major candidates as antioxidant compounds showing the capacity to inhibit the production of inflammatory mediators. However, caffeine and diterpenes may also exert negative effects, such as acute rise in blood pressure and serum lipids.

Conclusion: In light of the most recent evidence, coffee consumption seems to be favorably related with health and to protect by metabolic impairment.

© 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Contents

1. Introduction	2
2. Epidemiological versus experimental evidence	2
2.1. Diabetes mellitus, glucose tolerance, and insulin sensitivity	2
2.2. Hypertension	2
2.3. Dyslipidemia and lipid metabolism	2
3. Potential beneficial mechanisms of action	3
3.1. Glucose and insulin metabolism regulation	3
3.2. Lipid metabolism regulation	4
3.3. Effects on blood pressure	4
3.4. Antioxidant activity	4
4. Controversial effects and future prospective	4
5. Conclusion	5
Conflict of interest	5
References	5

* Corresponding author at: Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, Via Santa Sofia 87, 95123 Catania, Italy. Tel.: +39 095 3782182; fax: +39 095 3782177.

E-mail address: stefano.marventano@studium.unict.it (S. Marventano).

1. Introduction

Metabolic disorders, such as obesity, dysregulated glucose homeostasis, dyslipidemia, and abnormal elevation of systolic and diastolic blood pressure are important risk factors for cardiovascular disease (CVD) and are among the major contributors for overall mortality [1]. Overweight and obese population have rapidly increased worldwide leading to a concomitant rise of type 2 diabetes incidence, especially in the highest income regions [2]. Hypertension and dyslipidemia affect 20%–40% of the population, showing a significant association with elevated BMI, waist circumference, and fasting blood glucose [3]. Altogether, these conditions represent a major public health issue that could potentially be reduced by the adoption of a healthier lifestyle. Besides well-known risk factors, such as sedentary and smoking habits, dietary habits show a crucial impact toward metabolic disorders. Several investigations pointed out the important role of certain dietary patterns, such as the Mediterranean diet or the Dietary Approach to Stop Hypertension (DASH), as significant protective factors against metabolic disorders and CVD risk factors [4–7]. Cohort studies demonstrated positive effects of these dietary patterns in both Mediterranean and non-Mediterranean countries [8,9]. However, their application in non-Mediterranean areas is somehow limited and some important foods have not been taken into account when considering such dietary patterns. In the last ten years, research on coffee drinking has increased dramatically suggesting that coffee consumption is not as negative as it was hypothesized in earlier studies [10]. In a recent State-of-the-Art review, a moderate coffee consumption (2 to 3 cups per day) has shown potential benefits on cardiometabolic disease, cardiovascular health, and all-cause mortality [11]; although in other studies, high coffee consumption (>4 cups per day) could have adverse effects [12]. The findings recently published pointed out convincing hypotheses on its beneficial effects in preventing metabolic impairment and laboratory research on its components provided biological plausibility for its action [13]. In this narrative review, we report the most important epidemiological evidence on coffee consumption and metabolic impairment, showing the inconsistency between epidemiological and experimental studies as a result of the biological differences between short- versus long-time consumption. Furthermore, the most accredited hypotheses and mechanisms of action have been described.

2. Epidemiological versus experimental evidence

2.1. Diabetes mellitus, glucose tolerance, and insulin sensitivity

Two recent systematic reviews and meta-analyses analyzing the specific association between coffee (data from 28 studies with information on 1,109,272 participants) [14], and decaffeinated coffee (10 studies, 491,485 participants) [15] on incidence of type 2 diabetes found a nonlinear dose–response relationship between coffee intake and subsequent risk of type 2 diabetes, with a decrease of about 8% of risk for every 1 cup/day increment in coffee intake after adjustment for potential confounding factors (Table 1). Since similar results were shown for decaffeinated coffee, it is likely that the protective effect may exist aside from the influence of caffeine intake. Another systematic review including 13 cohort studies with 9473 type 2 diabetes cases and 47,387 participants, found a reduction in type 2 diabetes incidence in those subjects who consumed 4 or more cups per day compared with less than 2 cups drinkers [16] (Table 1). Advantage emerged comparing intake of filtered coffee over pot boiled and decaffeinated coffee over caffeinated coffee. However, by analyzing single studies reporting inconclusive results, a relation with factors that could explain such results (i.e., type of coffee or country) could not be found. In addition to the previous systematic reviews, more recent observational studies are in line with the hypothesis that coffee intake may be linked to a lower risk of diabetes [17–21], reduced risk of deterioration of glucose metabolism [22,23], and insulin resistance [24–27].

Generally, results from randomized controlled trials (RCT) exploring the effect of coffee consumption on glucose metabolism and biological risk factors for type 2 diabetes widely contrasted those from observational studies. A recent meta-analysis of RCT in people with type 2 diabetes reported substantial negative effect of caffeine intake on blood glucose control [28] (Table 1). As expected, a major limitation of the trials included in the pooled analysis was the short period of study. Indeed, the beneficial effects of caffeinated and decaffeinated instant coffee on glucose metabolism were found in a recent study that lasted 16 weeks [29], but studies exploring the acute effects following the meal reported opposite or inconclusive results. An experimental study conducted on healthy volunteers resulted in an increasing insulin response and decreased insulin sensitivity index after a 75 g oral glucose tolerance test, compared to water [30]. While in another RTC on healthy subjects, coffee consumption increased glucose concentration and lowered insulin concentrations in the first 30 min after a standardized meal [31]. Caffeinated coffee, after either a high or low glycemic index meal, significantly impaired acute blood glucose management and insulin insensitivity compared with ingestion of decaffeinated coffee [32,33], despite these effects being stronger after a lipid-rich meal [34]. Moreover, coffee consumption during a carbohydrate meal seems to decrease the insulin sensitivity of a second carbohydrate meal, even without an additional coffee intake [35]. Some other experimental studies reported poorly significant results of caffeinated coffee on postprandial glycemic tolerance and insulin sensitivity [36,37] or increase of coffee-derived compounds but no changes of markers of glucose metabolism at an oral glucose tolerance test were found [38].

2.2. Hypertension

Epidemiological studies exploring the role of coffee consumption on the development of hypertension showed inconclusive results. Among the several pooled analysis that have been conducted during last 10 years, the most recent meta-analysis of epidemiological studies, including 6 prospective cohorts with a total of 172,567 participants and 37,135 incident cases of hypertension, concluded that the summary relative risks (RRs) for hypertension was 1.09 (95% confidence interval (CI): 1.01, 1.18) for consumption of 1–3 cups per day, whereas no significant risk was found for higher categories (>3 cups/day) [39] (Table 1). A meta-analysis of experimental and observational epidemiological studies on coffee consumption and hypertension reported low-quality evidence, unable to show any statistically significant effect of coffee consumption on blood pressure or the risk of hypertension [40] (Table 1). Another meta-analysis investigating the role of coffee/caffeine intake in hypertensive subjects results in an acute increment of BP for ≥ 3 , without any long-term association between coffee intake and BP [41] (Table 1). These findings seem to confirm the results of a previous meta-analysis of RCT conducted with regard to the intake of both coffee and caffeine [42] (Table 1). They reported a significant rise of 2.04 mmHg (95% CI: 1.10, 2.99) in systolic blood pressure and 0.73 mmHg (95% CI: 0.14, 1.31) in diastolic blood pressure for pooled analysis of coffee and caffeine trials. When coffee trials and caffeine trials were analyzed separately, blood pressure elevations appeared to be significant only for caffeine but not for coffee, suggesting that despite the biochemical mechanism of action of caffeine supporting the biological plausibility that acute ingestion of such compounds may increase blood pressure, when ingested through coffee, the blood pressure effect of caffeine was somehow attenuated. It is noteworthy that most recent investigations found a significantly reduced risk of hypertension evaluated in both cross-sectional and prospective design only when analysis was stratified by smoking status [43,44].

2.3. Dyslipidemia and lipid metabolism

The early epidemiological studies published in the 1980s demonstrated a significant association between coffee consumption and

Table 1

Characteristics of meta-analysis and systematic review included in this review.

Author	Year	Number and design of the studies	Participants	Cases	Outcome	Exposure	Main results and RR (95% CI)
<i>Diabetes mellitus, glucose tolerance, and insulin sensitivity</i>							
Ding et al. [14]	2014	28 PCS	1,109,272	43,335	T2DM incidence	0 coffee cup/d 1 coffee cups/d 2 coffee cups/d 3 coffee cups/d 4 coffee cups/d 5 coffee cups/d 6 coffee cups/d	1 0.92 (0.90, 0.94) 0.85 (0.82, 0.88) 0.79 (0.75, 0.83) 0.75 (0.71, 0.80) 0.71 (0.65, 0.79) 0.67 (0.61, 0.74)
		26 PCS	1,096,647	50,595	T2DM incidence	Coffee lowest vs highest	0.71 (0.67, 0.76)
Jiang et al. [15]	2014	10 PCS	491,485	29,165	T2DM incidence	Decaffeinated coffee lowest vs highest	0.79 (0.69, 0.91)
		6 PCS	321,960	9302	T2DM incidence	Caffeine, lowest Vs highest	0.70 (0.65, 0.75)
Whitehead et al. [28]	2013	6 RCTs	73 T2DM individuals	N/A	Hypoglycemic episodes	Caffeine 400–500 mg	Increased awareness and decreased duration of hypoglycemic episodes
		1 RCT	8 GDM individuals	N/A	Blood glucose and insulin sensitivity	Caffeine 200–500 mg	Increased blood glucose (16%–28%) and insulin levels (19%–48%). Decreased insulin sensitivity by 14%–37%.
Muley et al. [16]	2012	13 PCS	12,47,387	9473	T2DM incidence	Coffee	Increased blood glucose (19%) and insulin level (29%) and reduced insulin sensitivity by 18%.
		6 RCTs	364 hypertensive individuals	N/A	Long-term effect on BP	Coffee or caffeine	T2DM incidence was reduced in subjects who drank 4–6 cups/d and 6–7 cups/d compared with <2 cups/d drinkers
<i>Hypertension</i>							
Mesas et al. [41]	2011	5 RCTs	85 hypertensive individuals	N/A	Acute effect on BP	Caffeine 200–300 mg)	SBP 8.14 mmHg (5.68, 10.61) DBP 5.7 mmHg (4.1, 7.4)
		6 RCTs	364 hypertensive individuals	N/A	Long-term effect on BP	Coffee or caffeine	No change in BP
Zhang et al. [39]	2011	6 PCS	172,567	37,135	Hypertension incidence	<1 coffee cup/d 1–3 coffee cups/d 3–5 coffee cups/d >5 coffee cups/d	1 1.09 (1.01, 1.18) 1.07 (0.96, 1.20) 1.08 (0.96, 1.21)
		16 RTCs	110	N/A	BP	Coffee	SBP 1.22 mmHg (0.52, 1.92) DBP 0.49 mmHg (–0.06, 1.04)
Noordzija et al. [42]	2005	16 RTCs	110	N/A	BP	Caffeine	SBP 4.16 mmHg (2.13, 6.20) DBP 2.41 mmHg (0.98, 3.84)
		12 RCT	1017	N/A	Serum lipids	Caffeine and coffee	SBP 2.04 mmHg (1.10, 2.99) DBP 0.73 mmHg (0.14, 1.31)
<i>Dyslipidemia and lipid metabolism</i>							
Cai et al. [54]	2012	12 RCT	1017	N/A	Serum lipids	Coffee 2.4 to 8.0 cups/day	TC 8.05 mg/dl (4.48, 11.62) LDL-C 5.44 mg/dl (1.38, 9.51) HDL-C –0.12 mg/dl (–0.62, 0.38) TG 12.55 mg/dl (3.47, 21.64)

CI, confidence interval; BP, blood pressure; DBP, diastolic blood pressure; GDM, gestational diabetes mellitus; HDL, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; N/A, not applicable; PCS, prospective cohort study; RTC, randomized controlled trial; SBP, systolic blood pressure; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TC, total cholesterol; TG, triglyceride.

increased serum cholesterol levels [45–48]. The hypercholesterolemic effect of coffee has been demonstrated to depend on the diterpenes cafestol and kahweol, and by the method of brewing [49]. Contrarily, filtered coffee consumption seems to have poor or no association with serum lipid levels compared to boiled coffee, maybe due to the retention of diterpenes by the paper filter [50]. Thus, results from epidemiological studies reported contrasting results with strong country-specific characteristics due to the different bioactive compounds contained in coffee in different countries and type of preparation method used [51–53].

Contrasting with observational studies, a recent meta-analysis of RCT evaluated the effects of coffee intake on serum lipids in 12 studies conducted on 1017 subjects [54] (Table 1). On average, drinking coffee for 45 days was associated with an increase of 8.1 mg/dl (95% CI: 4.5, 11.6) for total cholesterol, 5.4 mg/dl (95% CI: 1.4, 9.5) for LDL-C, and 12.6 mg/dl (95% CI: 3.5, 12.6) for triglycerides. Meta-regression analysis also revealed a positive dose–response relation between coffee intake and total cholesterol, LDL-C, and triglycerides. However, other more recent studies (thus not included in the previous meta-analysis) reported

poor or little influence on plasma lipids following acute ingestion of coffee [55] or even a suppression of postprandial hyperlipidemia [56], significant decrease of triglycerides, and increase of HDL-cholesterol [55].

3. Potential beneficial mechanisms of action

3.1. Glucose and insulin metabolism regulation

Despite the acute ingestion of caffeine resulting in a reduction of insulin sensitivity due to decreased glucose storage [57,58], this short-term effect cannot be observed after long-time consumption of coffee because of an overall impairment of effects of caffeine after continued intake [59]. Coffee has been reported to be the main contributor of a number of antioxidant compounds, including some polyphenols such as chlorogenic acids [60]. This family of polyphenols (mostly caffeic and ferulic acid) demonstrated the ability to affect some metabolic pathways [61,62]. In animal models, consumption of chlorogenic acids reduced fasting plasma glucose [63–65], increased sensitivity to insulin

[66], and slowed the appearance of glucose in circulation after glucose load [67,68]. This particular family of molecules showed a specific competitive inhibition of the glucose-6-phosphate translocase in rat liver microsomes [69] an enzyme highly involved in the regulation of homeostasis and blood glucose levels. At the cellular level, chlorogenic acids activate adenosine monophosphate-activated protein kinase (AMPK), a sensor and regulator of cellular energy balance, leading to beneficial metabolic effects, such as the inhibition of fatty acid synthesis and hepatic glucose production. Thus, chlorogenic acid by the activation of AMPK may contribute to lipid and glucose metabolism regulation [70]. Further hypotheses on the mechanism through which chlorogenic acids may prevent diabetes consist in their capacity to reduce sodium-dependent glucose transport in brush border membrane vesicles isolated from rat small intestine [71], and to inhibit α -amylase [72,73] and α -glucosidase activity [74,75], two key enzymes responsible for digestion of dietary carbohydrates, resulting in a reduction of intestinal absorption of glucose.

Together with phenolic compounds, trigonelline and sex hormone-binding globulin (SHBG) also demonstrated a protective effect against diabetes [67,76]. The vitamin B₃ precursor trigonelline has been shown to potentially improve insulin sensitivity in animal studies by inhibiting dipeptidylpeptidase-4 and α -glucosidase activities in both plasma and small intestine [77] and ameliorating the oxidative stress in type 2 diabetic rats downregulating the gene expressions involved with NADPH oxidase and mitochondrial electron transfer system [78]. SHBG have been related with type 2 diabetes since membranes of a variety of cells are able to specifically bind them with high affinity, and SHBG mediates the steroid-signaling system at the cell membrane through the SHBG receptors and exerting direct metabolic effects [79].

3.2. Lipid metabolism regulation

It has been reported that some components present in unfiltered coffee (i.e., cafestol and kahweol) raise serum lipids, but a clear involvement in the deposition of LDL-C and/or an oxidation of this lipid fraction has not been demonstrated. Accordingly, it is still debatable if coffee consumption can affect lipid metabolism in order to significantly increase cardiovascular risk [80]. On the contrary, it has been reported that coffee intake increase LDL-C resistance to oxidative modifications probably as a result of the incorporation of the phenolic acids in coffee into the cells [81]. An experimental study evaluating the effects of chlorogenic acids on lipid metabolism in diabetic rats found a significant increase in the concentrations of plasma and tissue (liver and kidney) lipids, cholesterol, triglycerides, free fatty acids and phospholipids, and LDL and very low-density lipoproteins, respectively, and a decrease in the concentration of HDL [82]. It was demonstrated that their action depended on the capacity to increase the activity of 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase in the liver and kidney and a decrease in the activities of lipoprotein lipase (LPL) and lecithin cholesterol acyl transferase (LCAT) in the plasma [82].

A number of epidemiological studies reported a positive association between coffee consumption and adiponectin levels, an insulin-sensitive hormone playing a central role in glucose and lipid metabolism, both in healthy individuals [83–86] and in those with metabolic syndrome-related disorders [87,88]. These studies remarked the inverse association between coffee consumption and obesity or visceral fat area. Experimental studies reported that coffee may play a role in the expression of adipo-R2 gene, which activate its downstream signaling pathways mainly by activating AMPK and peroxisome proliferator-activated receptors alpha (PPAR- α) [89]. Coffee polyphenols and melanoidins protected the liver from damage caused by a hypercaloric diet in an animal model, and this protection was partially mediated by a reduction in liver inflammation, through increases of adipo-R2 gene and anti-inflammatory cytokines IL-4 and IL-10 [90].

3.3. Effects on blood pressure

Despite caffeine inhibiting phosphodiesterase non-selectively, thereby causing an accumulation of cAMP, which can mediate a vasoconstrictive response [91], experimental studies reported that an acute increase in blood pressure due to coffee intake develops with rapid tolerance [92,93] and that intravenous caffeine is responsible for the increase in muscle sympathetic activity and blood pressure in both habitual and non-habitual coffee drinkers, but coffee intake led to increased blood pressure only in non-habitual coffee drinkers [94]. Several components of coffee demonstrate anti-hypertensive action [95]. Chlorogenic acids are hypothesized to exert anti-hypertensive effects by increasing nitric oxide bioavailability and improving endothelial function, which lead to a reduction of blood pressure [96]. Experimental studies also demonstrated that the depletion in roasted coffee of hydroxyhydroquinone, a particular fraction of chlorogenic acid, enhanced the anti-hypertensive effects of chlorogenic acids in a marginally dose-dependent manner [97]. Moreover, coffee is also rich in blood pressure-lowering minerals (i.e., potassium and magnesium) that may contribute to its effect on blood pressure [98].

3.4. Antioxidant activity

Oxidative stress is heavily involved in metabolism impairment pathways, as well as in the development of chronic subclinical inflammation that contribute to chronic disease incidence and progression. The inflammatory response could be mediated by many factors, such as the main phenolic compounds of coffee [99]. In particular, chlorogenic acids demonstrated strong antioxidant effect in a dose-response relationship as a result of the inhibition of the production of inflammatory mediators [100–102], by inhibiting protein tyrosine phosphatase 1B [103] and depressing the expression of pro-inflammatory cytokine genes [104,105]. These compounds also demonstrated decreased endothelial dysfunction [106] by modulating inflammatory NF- κ B activation via the redox-related c-Src/ERK and NIK/IKK pathways via the reduction of oxidative stress [107]. Diterpenes are multitasking molecules that play a role in the regulation of angiogenesis and inflammation processes [108,109]. The most studied effects of cafestol regard its capacity to regulate pathological angiogenesis [108]. Kahweol has demonstrated antioxidant properties by inhibiting both cyclo-oxygenase-2 (COX-2) expression and monocyte chemoattractant protein-1 (MCP-1) secretion in endothelial cells, key proteins mediating inflammatory processes [109]. It has been reported that cafestol and kahweol regulate Sp1 target proteins, which are involved in various biological processes such as differentiation, metabolism, cell growth, angiogenesis, and apoptosis [110]. Melanoidins, compounds formed during the roasting of coffee beans, have demonstrated strong antioxidant activity and to significantly inhibit lipid oxidation [111,112]. In an animal model of steatohepatitis, melanoidins protected liver from damage caused by a high-fat diet by a reduction in hepatic fat accumulation (through increased fatty acid β -oxidation), systemic and liver oxidative stress (through the glutathione system), liver inflammation (through modulation of genes), and expression and concentrations of proteins and cytokines related to inflammation [90]. Finally, caffeine itself and its metabolites theobromine and xanthine, have been reported to possess antioxidant properties, such as DNA-protection through quenching of hydroxyl radical generating systems [113].

4. Controversial effects and future perspective

Besides the potential beneficial effects of coffee consumption, great attention should be paid in order to explain its negative effects on human health. It has been often reported a U-shaped effect of coffee on several health outcomes [42, 114, 115], suggesting that a detrimental effect may occur at higher quantities of consumption. Moreover, results from epidemiological and experimental studies are rarely univocal, but

rather they are opposite and biased by methodological limits. Epidemiological studies provide insight into the long-term effects of coffee consumption but observational evidence cannot demonstrate causal relationship. Moreover, cross-sectional studies may have a lack of reliability due to the phenomenon of “reverse causation”, namely, an adaptation of coffee consumption after developing the disease. Prospective cohort studies should minimize such phenomenon, but control over time of coffee consumption may results difficult and the time distance between the exposure assessment (i.e., coffee intake at baseline) and the outcome evaluation may bias results. Thus, evidence from epidemiological studies is only in part demonstrated in the experimental setting, and potential confounders (i.e., cigarette smoking) may affect findings. The randomization process of RCT should, at least in part, attenuate the effects of confounders theoretically equally distributed over both intervention and control groups. However, compared to epidemiological studies, RCT are usually conducted over a limited period of time. Moreover, the effects follow generally a fixed dose of coffee (or caffeine) and controlled in a predetermined moment, thus estimating mostly acute effects of coffee and often not corresponding to “real-world” coffee drinking. Finally, regarding experimental studies, most of the data existing is based on *in vitro* and animal studies, therefore the relevance of findings for the application in humans is still unclear.

5. Conclusion

In conclusion, in light of the most recent epidemiological and experimental evidence, coffee consumption seems to be favorably related with health and to protect by metabolic impairment. Despite the mechanisms of action being not completely understood, its content in polyphenols and antioxidant compounds may be countering many of the negative effects reported in the early researches. Moreover, components with demonstrated harmful effects (i.e., caffeine and diterpenes) are nowadays also being reconsidered due to novel discoveries of new potential positive effects or new hypotheses on their interaction with metabolism regulation.

Conflict of interest

The authors declare that they have no conflict of interest.

References

- [1] G.B.D. Mortality, C. Causes of death, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study, *Lancet* 385 (2015) 117–171.
- [2] G. Danaei, M.M. Finucane, Y. Lu, G.M. Singh, M.J. Cowan, C.J. Paciorek, J.K. Lin, F. Farzadfar, Y.H. Khang, G.A. Stevens, M. Rao, M.K. Ali, L.M. Riley, C.A. Robinson, M. Ezzati, G. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating, National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants, *Lancet* 378 (2011) 31–40.
- [3] T. Hedner, S.E. Kjeldsen, K. Narkiewicz, State of global health—hypertension burden and control, *Blood Press* 21 (Suppl. 1) (2012) 1–2.
- [4] G. Grosso, A. Mistretta, A. Frigiola, S. Gruttadauria, A. Biondi, F. Basile, P. Vitaglione, N. D’Orazio, F. Galvano, Mediterranean diet and cardiovascular risk factors: a systematic review, *Crit. Rev. Food Sci. Nutr.* 54 (2014) 593–610.
- [5] S. Buscemi, D. Sprini, G. Grosso, F. Galvano, A. Nicolucci, G. Lucisano, F.M. Massenti, E. Amodio, G.B. Rini, Impact of lifestyle on metabolic syndrome in apparently healthy people, *Eat. Weight Disord.* 19 (2014) 225–232.
- [6] M. Siervo, J. Lara, S. Chowdhury, A. Ashor, C. Oggioni, J.C. Mathers, Effects of the dietary approach to stop hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta-analysis, *Br. J. Nutr.* (2014) 1–15.
- [7] G. Grosso, S. Marventano, J. Yang, A. Micek, A. Pajak, L. Scalfi, F. Galvano, S.N. Kales, A comprehensive meta-analysis on evidence of mediterranean diet and cardiovascular disease: are individual components equal? *Crit. Rev. Food Sci. Nutr.* (2015) [ahead of Print].
- [8] G. Grosso, A. Pajak, A. Mistretta, S. Marventano, T. Raciti, S. Buscemi, F. Drago, L. Scalfi, F. Galvano, Protective role of the Mediterranean diet on several cardiovascular risk factors: evidence from Sicily, Southern Italy, *Nutr. Metab. Cardiovasc. Dis.* 24 (2014) 370–377.
- [9] G. Grosso, U. Stepaniak, A. Micek, R. Topor-Madry, D. Stefler, K. Szafraniec, M. Bobak, A. Pajak, A Mediterranean-type diet is associated with better metabolic profile in urban Polish adults: results from the HAPIEE Study, *Metabolism* 64 (2015) 738–746.
- [10] J.V. Higdon, B. Frei, Coffee and health: a review of recent human research, *Crit. Rev. Food Sci. Nutr.* 46 (2006) 101–123.
- [11] J.H. O’Keefe, S.K. Bhatti, H.R. Patil, J.J. DiNicolantonio, S.C. Lucan, C.J. Lavie, Effects of habitual coffee consumption on cardiometabolic disease, cardiovascular health, and all-cause mortality, *J. Am. Coll. Cardiol.* 62 (2013) 1043–1051.
- [12] J. Liu, X. Sui, C.J. Lavie, J.R. Hebert, C.P. Earnest, J. Zhang, S.N. Blair, Association of coffee consumption with all-cause and cardiovascular disease mortality, *Mayo Clin. Proc.* 88 (2013) 1066–1074.
- [13] R.M. van Dam, Coffee and type 2 diabetes: from beans to beta-cells, *Nutr. Metab. Cardiovasc. Dis.* 16 (2006) 69–77.
- [14] M. Ding, S.N. Bhupathiraju, M. Chen, R.M. van Dam, F.B. Hu, Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose–response meta-analysis, *Diabetes Care* 37 (2014) 569–586.
- [15] X. Jiang, D. Zhang, W. Jiang, Coffee and caffeine intake and incidence of type 2 diabetes mellitus: a meta-analysis of prospective studies, *Eur. J. Nutr.* 53 (2014) 25–38.
- [16] A. Muley, P. Muley, M. Shah, Coffee to reduce risk of type 2 diabetes? A systematic review, *Curr. Diabetes Rev.* 8 (2012) 162–168.
- [17] T. Doo, Y. Morimoto, A. Steinbrecher, L.N. Kolonel, G. Maskarinec, Coffee intake and risk of type 2 diabetes: the multiethnic cohort, *Public Health Nutr.* (2013) 1–9.
- [18] A. Floegel, T. Pischon, M.M. Bergmann, B. Teucher, R. Kaaks, H. Boeing, Coffee consumption and risk of chronic disease in the European Prospective Investigation into Cancer and Nutrition (EPIC)–Germany study, *Am. J. Clin. Nutr.* 95 (2012) 901–908.
- [19] S.N. Bhupathiraju, A. Pan, V.S. Malik, J.E. Manson, W.C. Willett, R.M. van Dam, F.B. Hu, Caffeinated and caffeine-free beverages and risk of type 2 diabetes, *Am. J. Clin. Nutr.* 97 (2013) 155–166.
- [20] M. Kato, M. Noda, M. Inoue, T. Kadowaki, S. Tsugane, J.S. Group, Psychological factors, coffee and risk of diabetes mellitus among middle-aged Japanese: a population-based prospective study in the JPHC study cohort, *Endocr. J.* 56 (2009) 459–468.
- [21] S. Oba, C. Nagata, K. Nakamura, K. Fujii, T. Kawachi, N. Takatsuka, H. Shimizu, Consumption of coffee, green tea, oolong tea, black tea, chocolate snacks and the caffeine content in relation to risk of diabetes in Japanese men and women, *Br. J. Nutr.* 103 (2010) 453–459.
- [22] Y. Zhang, E.T. Lee, L.D. Cowan, R.R. Fabsitz, B.V. Howard, Coffee consumption and the incidence of type 2 diabetes in men and women with normal glucose tolerance: the Strong Heart Study, *Nutr. Metab. Cardiovasc. Dis.* 21 (2011) 418–423.
- [23] T. Hiratsuka, O. Tajima, K. Uezono, S. Tabata, H. Abe, K. Ohnaka, S. Kono, Coffee consumption, serum gamma-glutamyltransferase, and glucose tolerance status in middle-aged Japanese men, *Clin. Chem. Lab. Med.* 51 (2013) 1233–1239.
- [24] N.M. Pham, A. Nanri, T. Kochi, K. Kuwahara, H. Tsuruoka, K. Kurotani, S. Akter, I. Kabe, M. Sato, H. Hayabuchi, T. Mizoue, Coffee and green tea consumption is associated with insulin resistance in Japanese adults, *Metabolism* (2013) 400–408.
- [25] V. Lecoulter, G. Carrel, L. Egli, C. Binnert, A. Boss, E.L. Macmillan, R. Kreis, C. Boesch, C. Darimont, L. Tappy, Coffee consumption attenuates short-term fructose-induced liver insulin resistance in healthy men, *Am. J. Clin. Nutr.* 99 (2014) 268–275.
- [26] S.A. Rebello, C.H. Chen, N. Naidoo, W. Xu, J. Lee, K.S. Chia, E.S. Tai, R.M. van Dam, Coffee and tea consumption in relation to inflammation and basal glucose metabolism in a multi-ethnic Asian population: a cross-sectional study, *Nutr. J.* 10 (2011) 61.
- [27] R.C. Loopstra-Masters, A.D. Liese, S.M. Haffner, L.E. Wagenknecht, A.J. Hanley, Associations between the intake of caffeinated and decaffeinated coffee and measures of insulin sensitivity and beta cell function, *Diabetologia* 54 (2011) 320–328.
- [28] N. Whitehead, H. White, Systematic review of randomised controlled trials of the effects of caffeine or caffeinated drinks on blood glucose concentrations and insulin sensitivity in people with diabetes mellitus, *J. Hum. Nutr. Diet.* 26 (2013) 111–125.
- [29] K. Ohnaka, M. Ikeda, T. Maki, T. Okada, T. Shimazoe, M. Adachi, M. Nomura, R. Takayanagi, S. Kono, Effects of 16-week consumption of caffeinated and decaffeinated instant coffee on glucose metabolism in a randomized controlled trial, *J. Nutr. Metab.* 2012 (2012) 207426.
- [30] E. Rakvaag, L.O. Dragsted, Acute effects of light and dark roasted coffee on glucose tolerance: a randomized, controlled crossover trial in healthy volunteers, *Eur. J. Nutr.* (2015).
- [31] A. Gavrieli, E. Fragopoulou, C.S. Mantzoros, M. Yannakoulia, Gender and body mass index modify the effect of increasing amounts of caffeinated coffee on postprandial glucose and insulin concentrations; a randomized, controlled, clinical trial, *Metabolism* 62 (2013) 1099–1106.
- [32] L.L. Moisey, S. Kacker, A.C. Bickerton, L.E. Robinson, T.E. Graham, Caffeinated coffee consumption impairs blood glucose homeostasis in response to high and low glycemic index meals in healthy men, *Am. J. Clin. Nutr.* 87 (2008) 1254–1261.
- [33] J.A. Greenberg, D.R. Owen, A. Geliebter, Decaffeinated coffee and glucose metabolism in young men, *Diabetes Care* 33 (2010) 278–280.
- [34] M.S. Beaudoin, L.E. Robinson, T.E. Graham, An oral lipid challenge and acute intake of caffeinated coffee additively decrease glucose tolerance in healthy men, *J. Nutr.* 141 (2011) 574–581.
- [35] L.L. Moisey, L.E. Robinson, T.E. Graham, Consumption of caffeinated coffee and a high carbohydrate meal affects postprandial metabolism of a subsequent oral glucose tolerance test in young, healthy males, *Br. J. Nutr.* 103 (2010) 833–841.
- [36] J.D. Krebs, A. Parry-Strong, M. Weatherall, R.W. Carroll, M. Downie, A cross-over study of the acute effects of espresso coffee on glucose tolerance and insulin sensitivity in people with type 2 diabetes mellitus, *Metabolism* 61 (2012) 1231–1237.

- [37] N.M. Wedick, A.M. Brennan, Q. Sun, F.B. Hu, C.S. Mantzoros, R.M. van Dam, Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial, *Nutr. J.* 10 (2011) 93.
- [38] K. Kempf, C. Herder, I. Erlund, H. Kolb, S. Martin, M. Carstensen, W. Koenig, J. Sundvall, S. Bidel, S. Kuha, J. Tuomilehto, Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial, *Am. J. Clin. Nutr.* 91 (2010) 950–957.
- [39] Z. Zhang, G. Hu, B. Caballero, L. Appel, L. Chen, Habitual coffee consumption and risk of hypertension: a systematic review and meta-analysis of prospective observational studies, *Am. J. Clin. Nutr.* 93 (2011) 1212–1219.
- [40] M. Steffen, C. Kuhle, D. Hensrud, P.J. Erwin, M.H. Murad, The effect of coffee consumption on blood pressure and the development of hypertension: a systematic review and meta-analysis, *J. Hypertens.* 30 (2012) 2245–2254.
- [41] A.E. Mesas, L.M. Leon-Munoz, F. Rodriguez-Artalejo, E. Lopez-Garcia, The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis, *Am. J. Clin. Nutr.* 94 (2011) 1113–1126.
- [42] M. Noordzij, C.S. Uiterwaal, L.R. Arends, F.J. Kok, D.E. Grobbee, J.M. Geleijnse, Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials, *J. Hypertens.* 23 (2005) 921–928.
- [43] G. Grosso, U. Stepaniak, A. Micek, R. Topor-Madry, H. Pikhart, K. Szafraniec, A. Pajak, Association of daily coffee and tea consumption and metabolic syndrome: results from the Polish arm of the HAPIEE Study, *Eur. J. Nutr.* (2014) (ahead of Print).
- [44] G. S.U. Grosso, M. Polak, A. Micek, R. Topor-Madry, D. Stefler, K. Szafraniec, A. Pajak, Coffee consumption and risk of hypertension in the Polish arm of the HAPIEE cohort study, *Eur. J. Clin. Nutr.* (2015) [(ahead of print)].
- [45] D.S. Thelle, E. Arnesen, O.H. Forde, The Tromso Heart Study. Does coffee raise serum cholesterol? *N. Engl. J. Med.* 308 (1983) 1454–1457.
- [46] A. Aro, P. Pietinen, U. Uusitalo, J. Tuomilehto, Coffee and tea consumption, dietary fat intake and serum cholesterol concentration of Finnish men and women, *J. Intern. Med.* 226 (1989) 127–132.
- [47] P. Pietinen, J. Geboers, H. Kesteloot, Coffee consumption and serum cholesterol: an epidemiological study in Belgium, *Int. J. Epidemiol.* 17 (1988) 98–104.
- [48] E. Arnesen, O.H. Forde, D.S. Thelle, Coffee and serum cholesterol, *Br. Med. J.* 288 (1984) 1960.
- [49] R. Urgert, M.B. Katan, The cholesterol-raising factor from coffee beans, *Annu. Rev. Nutr.* 17 (1997) 305–324.
- [50] A.A. Bak, D.E. Grobbee, The effect on serum cholesterol levels of coffee brewed by filtering or boiling, *N. Engl. J. Med.* 321 (1989) 1432–1437.
- [51] N. Naidoo, C. Chen, S.A. Rebello, K. Speer, E.S. Tai, J. Lee, S. Buchmann, I. Koelling-Speer, R.M. van Dam, Cholesterol-raising diterpenes in types of coffee commonly consumed in Singapore, Indonesia and India and associations with blood lipids: a survey and cross sectional study, *Nutr. J.* 10 (2011) 48.
- [52] E. Lopez-Garcia, R.M. van Dam, W.C. Willett, E.B. Rimm, J.E. Manson, M.J. Stampfer, K.M. Rexrode, F.B. Hu, Coffee consumption and coronary heart disease in men and women: a prospective cohort study, *Circulation* 113 (2006) 2045–2053.
- [53] G. Grosso, S. Marventano, F. Galvano, A. Pajak, A. Mistretta, Factors associated with metabolic syndrome in a Mediterranean population: role of caffeinated beverages, *J. Epidemiol.* 24 (2014) 327–333.
- [54] L. Cai, D. Ma, Y. Zhang, Z. Liu, P. Wang, The effect of coffee consumption on serum lipids: a meta-analysis of randomized controlled trials, *Eur. J. Clin. Nutr.* 66 (2012) 872–877.
- [55] A. Zargar, C. Auttapibarn, S.H. Hong, T.J. Larson, K.H. Hayworth, M.K. Ito, The effect of acute cafe latte ingestion on fasting serum lipid levels in healthy individuals, *J. Clin. Lipidol.* 7 (2013) 165–168.
- [56] T. Murase, Y. Yokoi, K. Misawa, H. Ominami, Y. Suzuki, Y. Shibuya, T. Hase, Coffee polyphenols modulate whole-body substrate oxidation and suppress postprandial hyperglycaemia, hyperinsulinaemia and hyperlipidaemia, *Br. J. Nutr.* 107 (2012) 1757–1765.
- [57] F.S. Thong, W. Derave, B. Kiens, T.E. Graham, B. Urso, J.F. Wojtaszewski, B.F. Hansen, E.A. Richter, Caffeine-induced impairment of insulin action but not insulin signaling in human skeletal muscle is reduced by exercise, *Diabetes* 51 (2002) 583–590.
- [58] F.S. Thong, T.E. Graham, Caffeine-induced impairment of glucose tolerance is abolished by beta-adrenergic receptor blockade in humans, *J. Appl. Physiol.* 92 (2002) 2347–2352.
- [59] T.E. Graham, E. Hibbert, P. Sathasivam, Metabolic and exercise endurance effects of coffee and caffeine ingestion, *J. Appl. Physiol.* 85 (1998) 883–889.
- [60] G. Grosso, U. Stepaniak, R. Topor-Madry, K. Szafraniec, A. Pajak, Estimated dietary intake and major food sources of polyphenols in the Polish arm of the HAPIEE Study, *Nutrition* 30 (2014) 1398–1403.
- [61] J.B. Park, Isolation and quantification of major chlorogenic acids in three major instant coffee brands and their potential effects on H₂O₂-induced mitochondrial membrane depolarization and apoptosis in PC-12 cells, *Food Funct.* 4 (2013) 1632–1638.
- [62] J. Godos, F.R. Pluchinotta, S. Marventano, S. Buscemi, G. Li Volti, F. Galvano, G. Grosso, Coffee components and cardiovascular risk: beneficial and detrimental effects, *Int. J. Food Sci. Nutr.* 65 (2014) 925–936.
- [63] A. Andrade-Cetto, H. Wiedenfeld, Hypoglycemic effect of *Cecropia obtusifolia* on streptozotocin diabetic rats, *J. Ethnopharmacol.* 78 (2001) 145–149.
- [64] D.V. Rodriguez de Sotillo, M. Hadley, Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats, *J. Nutr. Biochem.* 13 (2002) 717–726.
- [65] D.V. Rodriguez de Sotillo, M. Hadley, J.E. Sotillo, Insulin receptor exon 11 +/- is expressed in Zucker (fa/fa) rats, and chlorogenic acid modifies their plasma insulin and liver protein and DNA, *J. Nutr. Biochem.* 17 (2006) 63–71.
- [66] J. Shearer, A. Farah, T. de Paulis, D.P. Bracy, R.R. Pencek, T.E. Graham, D.H. Wasserman, Quinides of roasted coffee enhance insulin action in conscious rats, *J. Nutr.* 133 (2003) 3529–3532.
- [67] A.E. van Dijk, M.R. Olthof, J.C. Meeuse, E. Seebus, R.J. Heine, R.M. van Dam, Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance, *Diabetes Care* 32 (2009) 1023–1025.
- [68] B.K. Bassoli, P. Cassolla, G.R. Borba-Murad, J. Constantini, C.L. Salgueiro-Pagadigorria, R.B. Bazotte, R.S. da Silva, H.M. de Souza, Chlorogenic acid reduces the plasma glucose peak in the oral glucose tolerance test: effects on hepatic glucose release and glycaemia, *Cell Biochem. Funct.* 26 (2008) 320–328.
- [69] W.J. Arion, W.K. Canfield, F.C. Ramos, P.W. Schindler, H.J. Burger, H. Hemmerle, G. Schubert, P. Below, A.W. Herling, Chlorogenic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6-phosphatase, *Arch. Biochem. Biophys.* 339 (1997) 315–322.
- [70] K.W. Ong, A. Hsu, B.K. Tan, Anti-diabetic and anti-lipidemic effects of chlorogenic acid are mediated by ampk activation, *Biochem. Pharmacol.* 85 (2013) 1341–1351.
- [71] C.A. Welsch, P.A. Lachance, B.P. Wasserman, Dietary phenolic compounds: inhibition of Na⁺-dependent D-glucose uptake in rat intestinal brush border membrane vesicles, *J. Nutr.* 119 (1989) 1698–1704.
- [72] I. Funke, M.F. Melzig, Effect of different phenolic compounds on alpha-amylase activity: screening by microplate-reader based kinetic assay, *Pharmazie* 60 (2005) 796–797.
- [73] Y. Narita, K. Inouye, Kinetic analysis and mechanism on the inhibition of chlorogenic acid and its components against porcine pancreas alpha-amylase isozymes I and II, *J. Agric. Food Chem.* 57 (2009) 9218–9225.
- [74] A. Ishikawa, H. Yamashita, M. Hiemori, E. Inagaki, M. Kimoto, M. Okamoto, H. Tsuji, A.N. Memon, A. Mohammad, Y. Natori, Characterization of inhibitors of postprandial hyperglycemia from the leaves of *Nerium indicum*, *J. Nutr. Sci. Vitaminol.* 53 (2007) 166–173.
- [75] S. Adisakwattana, P. Chantarasinlapin, H. Thammarat, S. Yibchok-Anun, A series of cinnamic acid derivatives and their inhibitory activity on intestinal alpha-glucosidase, *J. Enzyme Inhib. Med. Chem.* 24 (2009) 1194–1200.
- [76] A. Goto, Y. Song, B.H. Chen, J.E. Manson, J.E. Buring, S. Liu, Coffee and caffeine consumption in relation to sex hormone-binding globulin and risk of type 2 diabetes in postmenopausal women, *Diabetes* 60 (2011) 269–275.
- [77] K. Hamden, A. Bengara, Z. Amri, A. Elfeki, Experimental diabetes treated with trigonelline: effect on key enzymes related to diabetes and hypertension, beta-cell and liver function, *Mol. Cell. Biochem.* 381 (2013) 85–94.
- [78] O. Yoshinari, A. Takenake, K. Igarashi, Trigonelline ameliorates oxidative stress in type 2 diabetic Goto-Kakizaki rats, *J. Med. Food* 16 (2013) 34–41.
- [79] E.L. Ding, Y. Song, J.E. Manson, D.J. Hunter, C.C. Lee, N. Rifai, J.E. Buring, J.M. Gaziano, S. Liu, Sex hormone-binding globulin and risk of type 2 diabetes in women and men, *N. Engl. J. Med.* 361 (2009) 1152–1163.
- [80] A. Suzuki, A. Fujii, H. Jokura, I. Tokimitsu, T. Hase, I. Saito, Hydroxyhydroquinone interferes with the chlorogenic acid-induced restoration of endothelial function in spontaneously hypertensive rats, *Am. J. Hypertens.* 21 (2008) 23–27.
- [81] G.S. Yukawa, M. Mune, H. Otani, Y. Tone, X.M. Liang, H. Iwahashi, W. Sakamoto, Effects of coffee consumption on oxidative susceptibility of low-density lipoproteins and serum lipid levels in humans, *Biochemistry (Mosc)* 69 (2004) 70–74.
- [82] K. Karthikesan, L. Pari, V.P. Menon, Antihyperlipidemic effect of chlorogenic acid and tetrahydrocurcumin in rats subjected to diabetogenic agents, *Chem. Biol. Interact.* 188 (2010) 643–650.
- [83] K. Mure, S. Maeda, C. Mukoubayashi, K. Mugitani, M. Iwane, F. Kinoshita, O. Mohara, T. Takeshita, Habitual coffee consumption inversely associated with metabolic syndrome-related biomarkers involving adiponectin, *Nutrition* 29 (2013) 982–987.
- [84] K. Yamashita, H. Yatsuya, T. Muramatsu, H. Toyoshima, T. Murohara, K. Takamashi, Association of coffee consumption with serum adiponectin, leptin, inflammation and metabolic markers in Japanese workers: a cross-sectional study, *Nutr. Diabetes* 2 (2012) e33.
- [85] K. Murakami, S. Sasaki, K. Uenishi, N. Japan Dietetic Students' study for, G. Biomarkers, Serum adiponectin concentration in relation to macronutrient and food intake in young Japanese women, *Nutrition* 29 (2013) 1315–1320.
- [86] T. Imatoh, S. Tanihara, M. Miyazaki, Y. Momose, Y. Uryu, H. Une, Coffee consumption but not green tea consumption is associated with adiponectin levels in Japanese males, *Eur. J. Nutr.* 50 (2011) 279–284.
- [87] L. Ostrowska, J. Fiedorczuk, E. Adamska, Effect of diet and other factors on serum adiponectin concentrations in patients with type 2 diabetes, *Rocz. Panstw. Zakl. Hig.* 64 (2013) 61–66.
- [88] C.J. Williams, J.L. Fargnoli, J.J. Hwang, R.M. van Dam, G.L. Blackburn, F.B. Hu, C.S. Mantzoros, Coffee consumption is associated with higher plasma adiponectin concentrations in women with or without type 2 diabetes: a prospective cohort study, *Diabetes Care* 31 (2008) 504–507.
- [89] C. de Oliveira, A.B. de Mattos, C.B. Silva, J.F. Mota, J.C. Zemdegs, Nutritional and hormonal modulation of adiponectin and its receptors adiponectin1 and adiponectin2, *Vitam. Horm.* 90 (2012) 57–94.
- [90] P. Vitaglione, F. Morisco, G. Mazzone, D.C. Amoroso, M.T. Ribocco, A. Romano, V. Fogliano, N. Caporaso, G. D'Argenio, Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins, *Hepatology* 52 (2010) 1652–1661.
- [91] D. Echeverri, F.R. Montes, M. Cabrera, A. Galan, A. Prieto, Caffeine's vascular mechanisms of action, *Int. J. Vasc. Med.* 2010 (2010) 834060.
- [92] D. Robertson, D. Wade, R. Workman, R.L. Woosley, J.A. Oates, Tolerance to the humoral and hemodynamic effects of caffeine in man, *J. Clin. Invest.* 67 (1981) 1111–1117.

- [93] H.P. Ammon, P.R. Bieck, D. Mandalaz, E.J. Verspohl, Adaptation of blood pressure to continuous heavy coffee drinking in young volunteers. A double-blind crossover study, *Br. J. Clin. Pharmacol.* 15 (1983) 701–706.
- [94] R. Corti, C. Binggeli, I. Sudano, L. Spieker, E. Hanseler, F. Ruschitzka, W.F. Chaplin, T.F. Luscher, G. Noll, Coffee acutely increases sympathetic nerve activity and blood pressure independently of caffeine content: role of habitual versus nonhabitual drinking, *Circulation* 106 (2002) 2935–2940.
- [95] Y. Zhao, J. Wang, O. Ballevre, H. Luo, W. Zhang, Antihypertensive effects and mechanisms of chlorogenic acids, *Hypertens. Res.* 35 (2012) 370–374.
- [96] A. Suzuki, M. Yamamoto, H. Jokura, A. Fujii, I. Tokimitsu, T. Hase, I. Saito, Ferulic acid restores endothelium-dependent vasodilation in aortas of spontaneously hypertensive rats, *Am. J. Hypertens.* 20 (2007) 508–513.
- [97] T. Yamaguchi, A. Chikama, K. Mori, T. Watanabe, Y. Shioya, Y. Katsuragi, I. Tokimitsu, Hydroxyhydroquinone-free coffee: a double-blind, randomized controlled dose–response study of blood pressure, *Nutr. Metab. Cardiovasc. Dis.* 18 (2008) 408–414.
- [98] J.M. Geleijnse, Habitual coffee consumption and blood pressure: an epidemiological perspective, *Vasc. Health Risk Manag.* 4 (2008) 963–970.
- [99] T. Ranheim, B. Halvorsen, Coffee consumption and human health—beneficial or detrimental?—Mechanisms for effects of coffee consumption on different risk factors for cardiovascular disease and type 2 diabetes mellitus, *Mol. Nutr. Food Res.* 49 (2005) 274–284.
- [100] T. Krakauer, The polyphenol chlorogenic acid inhibits staphylococcal exotoxin-induced inflammatory cytokines and chemokines, *Immunopharmacol. Immunotoxicol.* 24 (2002) 113–119.
- [101] M.D. dos Santos, M.C. Almeida, N.P. Lopes, G.E. de Souza, Evaluation of the anti-inflammatory, analgesic and antipyretic activities of the natural polyphenol chlorogenic acid, *Biol. Pharm. Bull.* 29 (2006) 2236–2240.
- [102] J.A. Gomez-Ruiz, D.S. Leake, J.M. Ames, In vitro antioxidant activity of coffee compounds and their metabolites, *J. Agric. Food. Chem.* 55 (2007) 6962–6969.
- [103] V.S. Muthusamy, C. Saravanababu, M. Ramanathan, R. Bharathi Raja, S. Sudhagar, S. Anand, B.S. Lakshmi, Inhibition of protein tyrosine phosphatase 1B and regulation of insulin signalling markers by caffeoyl derivatives of chicory (*Cichorium intybus*) salad leaves, *Br. J. Nutr.* 104 (2010) 813–823.
- [104] Y. Matsuda, M. Kobayashi, R. Yamauchi, M. Ojika, M. Hiramitsu, T. Inoue, T. Katagiri, A. Murai, F. Horio, Coffee and caffeine improve insulin sensitivity and glucose tolerance in C57BL/6j mice fed a high-fat diet, *Biosci. Biotechnol. Biochem.* 75 (2011) 2309–2315.
- [105] Y. Fukushima, M. Kasuga, K. Nakao, I. Shimomura, Y. Matsuzawa, Effects of coffee on inflammatory cytokine gene expression in mice fed high-fat diets, *J. Agric. Food Chem.* 57 (2009) 11100–11105.
- [106] E. Lopez-Garcia, R.M. van Dam, L. Qi, F.B. Hu, Coffee consumption and markers of inflammation and endothelial dysfunction in healthy and diabetic women, *Am. J. Clin. Nutr.* 84 (2006) 888–893.
- [107] S.R. Kim, Y.R. Jung, D.H. Kim, H.J. An, M.K. Kim, N.D. Kim, H.Y. Chung, Caffeic acid regulates LPS-induced NF-kappaB activation through NIK/IKK and c-src/ERK signaling pathways in endothelial cells, *Arch. Pharm. Res.* (2013).
- [108] S. Wang, Y.C. Yoon, M.J. Sung, H.J. Hur, J.H. Park, Antiangiogenic properties of cafestol, a coffee diterpene, in human umbilical vein endothelial cells, *Biochem. Biophys. Res. Commun.* 421 (2012) 567–571.
- [109] C. Cardenas, A.R. Quesada, M.A. Medina, Anti-angiogenic and anti-inflammatory properties of kahweol, a coffee diterpene, *PLoS One* 6 (2011) e23407.
- [110] K.A. Lee, J.I. Chae, J.H. Shim, Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma, *J. Biomed. Sci.* 19 (2012) 60.
- [111] R.C. Borrelli, A. Visconti, C. Mennella, M. Anese, V. Fogliano, Chemical characterization and antioxidant properties of coffee melanoidins, *J. Agric. Food Chem.* 50 (2002) 6527–6533.
- [112] S. Shizuuchi, F. Hayase, Antioxidative activity of the blue pigment formed in a D-xylose-glycine reaction system, *Biosci. Biotechnol. Biochem.* 67 (2003) 54–59.
- [113] S. Azam, N. Hadi, N.U. Khan, S.M. Hadi, Antioxidant and prooxidant properties of caffeine, theobromine and xanthine, *Med. Sci. Monit.* 9 (2003) BR325–BR330.
- [114] A. Paganini-Hill, C.H. Kawas, M.M. Corrada, Non-alcoholic beverage and caffeine consumption and mortality: the Leisure World Cohort Study, *Prev. Med.* 44 (2007) 305–310.
- [115] L.F. Andersen, D.R. Jacobs Jr., M.H. Carlsen, R. Blomhoff, Consumption of coffee is associated with reduced risk of death attributed to inflammatory and cardiovascular diseases in the Iowa Women's health study, *Am. J. Clin. Nutr.* 83 (2006) 1039–1046.